1 INTRODUCTION

In selected patients, the combination of nondihydropyrimidine calcium channel blockers with beta-blockers might provide an effect superior to either drug alone; however, serious and sometimes fatal additive cardiovascular effects occur. This report indicates that CYP2D6 PM status could be a special vulnerability factor for the combination of verapamil and metoprolol.

Calcium channel blockers (CCB) are prescribed for the treatment of arrhythmia and hypertension. Verapamil is a class IV antidysrhythmic drug, which acts by blocking voltage-sensitive calcium channels. Verapamil is rapidly absorbed and undergoes extensive first-pass degradation (10%–20% bioavailability), primarily via O- and N-dealkylation by hepatic cytochrome P450 (CYP) 3A4 forming norverapamil, a pharmacologically active metabolite of verapamil. Verapamil and its metabolite have the ability to inhibit transmembrane calcium flux in cardiac cells and smooth muscle cells. Its pharmacological effects are reduction in heart rate and myocardial contractility, slow atrioventricular (A–V) node conduction, and reduction in the peripheral vascular resistance. Verapamil inhibit CYP3A4 and P-glycoprotein–mediated drug transport, which may alter the intestinal absorption of several drugs and their distribution into peripheral tissues and the central nervous system. During overdose, half-life of verapamil may be greatly prolonged (up to 10 days); this may be due to saturation of the hepatic enzyme or rate-limiting absorption.

Beta-adrenergic blockers (BB) are used in the treatment of hypertension and heart failure. Metoprolol is a selective b1-adrenergic blocking agent, and it is lipophilic and predominately metabolized in the liver via cytochrome CYP2D6. Blockade of the myocardial b1 receptor reduces heart rate, myocardial contractility, and cardiac output. Dizziness, bradycardia, and hypotension are observed as adverse reactions at therapeutic plasma levels.

Studies from the 1980s suggested that in selected patients, the combination of nondihydropyrimidine CCBs like verapamil with BBs like metoprolol might provide an effect superior to either drug alone; however, many studies and case reports have provided data that confirm serious and sometimes fatal
2 | CASE REPORT

A 76-year-old woman who was suffering from persistent atrial fibrillation, atrial hypertension, and chronic obstructive lung disease and who had previously been in treatment for ovarian cancer, colon cancer, and breast cancer was hospitalized due to an INR (international normalized ratio) above 9.0. At the time of hospitalization, she was in treatment with verapamil 120 mg daily and warfarin for persistent atrial fibrillation. A complete list of medicine at the time of hospitalization is available in Table 1.

The patient had recently had a gastroscopy revealing a fungal infection and a high level of gastric acid. Her family physician therefore initiated a treatment with a short course of fluconazole and pantoprazole. After 2 days of treatment with fluconazole, her physician measured an INR of 5.6. After a control visit 2 days later, the INR had increased to eight and the patient was hospitalized.

At the time of hospitalization, her heart rate was 96 bpm. During the evening on the third day of hospitalization, an electrocardiogram (ECG) showed atrial fibrillation and a junior physician prescribed Selo-zok® (metoprolol), 50 mg slow-release tablet. According to the latest guideline from the European Society of Cardiology, a patient in need of acute rhythm control can have digoxin added to the treatment with verapamil, if the patient has a left ventricular ejection fraction of above 40 and the heart rate is above 110 bpm. The patient was not known with previous heart failure or reduced ventricular ejection fraction, and a suspicion of heart failure was not mentioned in the hospital records at this time. The next morning an experienced doctor discontinued metoprolol during the morning rounds, as she was aware of a potential interaction between metoprolol and verapamil. The patient was well and had no signs of acute illnesses. Only one tablet of metoprolol 50 mg had been administered to the patient. After lunch on the same day, the patient developed bradycardia and hypotension and infusion with isoprenaline was initiated (see Table 2 for details). An interaction between verapamil and metoprolol was suspected. The condition progressed and despite of isoprenaline, atropine, and external pacing, her blood pressure was immeasurable and her heart rate decreased (Figure 1).

She was transferred to another hospital for the insertion of a temporary pace wire. On arrival at the second hospital, the patient was completely unresponsive, she had been intubated in the ambulance and her pulse had decreased to ten beats per minute. Blood analysis showed serious metabolic acidosis. Further treatment was considered futile, and the patient was declared dead at 19.30 on the third day of hospitalization. A medicolegal autopsy was performed, and a standard forensic toxicological analysis was performed on blood withdrawn from the femoral vein at autopsy shortly after her death, see Table 3 for the blood concentrations of drugs. The autopsy showed right atrial dilatation, but otherwise normal right and left ventricles, normal heart valves, and no signs of acute coronary syndrome, and the liver was normal.

3 | DISCUSSION

Most importantly, the toxicological analysis revealed a whole blood concentration of metoprolol of 0.50 mg/kg and verapamil of 0.24 mg/kg.
Morphine, oxycodone, and fentanyl were not assessed to be of importance due to supportive treatment with respirator. Other drugs were found at levels normally seen in treatment or below.

Known therapeutic whole blood concentration ranges of verapamil are 0.015-0.19 mg/kg and of metoprolol are 0.039-0.55 mg/kg (recalculated from plasma values using blood/plasma ratio 1.1 for metoprolol and 0.75 for verapamil). Known metoprolol whole blood concentrations from drug-induced fatalities average 60 mg/kg (range 4.7-142) and verapamil concentrations average 11 mg/kg (range 0.9-85). In this case, one single tablet of metoprolol 50 mg was administered, and the blood concentration of metoprolol was found to be in the high end of the therapeutic concentration range almost 24 hours later, despite of an elimination half-life of metoprolol slow-release tablets of 3-4 hours. Postmortem redistribution might have caused an increase in concentrations; however, the patient died from a serious cardiac.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Age (y)</th>
<th>Gender</th>
<th>Dose (mg/d)</th>
<th>Serum/ blood level (mg/kg)</th>
<th>Symptoms</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mills TA 2004&lt;sup&gt;25&lt;/sup&gt;</td>
<td>61</td>
<td>F</td>
<td>Verapamil 360 Propranolol 40</td>
<td>Sinus bradycardia (26/min) Junctional escape rhythm</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>F</td>
<td>Atenolol 100 Diltiazem 360</td>
<td>Hypotension (87/55) Atrial bradycardia (12/min) Junctional escape rhythm</td>
<td></td>
<td>Atropine, temporary pacing</td>
</tr>
<tr>
<td></td>
<td>62</td>
<td>F</td>
<td>Diltiazem 240 Enalapril</td>
<td>Sinus bradycardia (31/min) Junctional escape rhythm</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td></td>
<td>73</td>
<td>F</td>
<td>Diltiazem 120 Atenolol 25</td>
<td>Sinus arrest Junctional escape rhythm</td>
<td></td>
<td>Atropine, dopamine, external pacing</td>
</tr>
<tr>
<td></td>
<td>73</td>
<td>F</td>
<td>Metoprolol 50 Diltiazem 180</td>
<td>Sinus bradycardia (34/min) Junctional escape rhythm</td>
<td></td>
<td>Stopped treatment</td>
</tr>
<tr>
<td></td>
<td>61</td>
<td>M</td>
<td>Nadolol 40 Diltiazem 300</td>
<td>Sinus arrest Junctional escape rhythm</td>
<td></td>
<td>Atropine, temporary pacemaker</td>
</tr>
<tr>
<td></td>
<td>62</td>
<td>M</td>
<td>Verapamil 360 Atenolol 25</td>
<td>Sinus bradycardia (54/min)</td>
<td></td>
<td>Cessation of treatment Complicated by chronic kidney disease and hemodialysis</td>
</tr>
<tr>
<td></td>
<td>73</td>
<td>F</td>
<td>Verapamil 480 Metoprolol 200</td>
<td>Hypotension (98/64) Sinus bradycardia (39/min) Junctional escape rhythm</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>M</td>
<td>Metoprolol 150 Amlodipine 20</td>
<td>No symptoms, sinus pause revealed by holter</td>
<td></td>
<td>Metoprolol stopped</td>
</tr>
<tr>
<td>Sakurai H 2000&lt;sup&gt;24&lt;/sup&gt;</td>
<td>54</td>
<td>M</td>
<td>Verapamil 360 Metoprolol 200</td>
<td>Shock, Pulmonary edema, bradycardia (56/min) Junctional escape rhythm</td>
<td></td>
<td>Dopamine, furosemide</td>
</tr>
<tr>
<td></td>
<td>69</td>
<td>F</td>
<td>Verapamil 240 Metoprolol 100</td>
<td>Shock, pulmonary congestion, sinus bradycardia (44/min)</td>
<td></td>
<td>Isoprenaline</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>F</td>
<td>Verapamil 160 Pindolol 10</td>
<td>Hypotension, sinus bradycardia (40/min)</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>M</td>
<td>Verapamil 480 Propranolol 160</td>
<td>Hypotension, bradycardia (32/min), AV nodal rhythm</td>
<td></td>
<td>Isoproterenol, dopamine</td>
</tr>
<tr>
<td></td>
<td>55</td>
<td>F</td>
<td>Verapamil 80 Propranolol 80</td>
<td>Hypotension, bradycardia</td>
<td></td>
<td>Epinephrine</td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>F</td>
<td>Verapamil 60 Atenolol 40</td>
<td>0.367 Shock, bradycardia, AV nodal rhythm</td>
<td></td>
<td>Calcium chloride</td>
</tr>
<tr>
<td></td>
<td>42</td>
<td>M</td>
<td>Verapamil 120 Atenolol 50</td>
<td>0.65 Shock, sinus arrest</td>
<td></td>
<td>Dopamine, temporary pacing</td>
</tr>
<tr>
<td></td>
<td>57</td>
<td>F</td>
<td>Verapamil 60 Atenolol 40</td>
<td>0.45 Shock, complete heart block</td>
<td></td>
<td>Dopamine, dobutamine, noradrenaline, temporary pacing, intraaortic balloon</td>
</tr>
<tr>
<td></td>
<td>78</td>
<td>F</td>
<td>Verapamil 240 Metoprolol 100</td>
<td>1.7 Shock, complete heart block</td>
<td></td>
<td>Calcium gluconate</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>F</td>
<td>Verapamil 160 Atenolol 50</td>
<td></td>
<td>Shock, pulmonary congestion, electromechanical dissociation</td>
<td></td>
</tr>
<tr>
<td>Robson RH 1982&lt;sup&gt;26&lt;/sup&gt;</td>
<td>60</td>
<td>M</td>
<td>Nifedipine 60 Atenolol 100</td>
<td>Congestive heart failure</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td>Staffurth JS 1981&lt;sup&gt;20&lt;/sup&gt;</td>
<td>47</td>
<td>M</td>
<td>Nifedipine 30 Propranolol 640</td>
<td>Hypotension (unrecordable), pulse rate 48/min</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
<tr>
<td>Eisenberg JNH 1984&lt;sup&gt;21&lt;/sup&gt;</td>
<td>46</td>
<td>M</td>
<td>Verapamil 240 Metoprolol 200</td>
<td>Bradycardia (44/min), Wenckebach AV block</td>
<td></td>
<td>Cessation of verapamil</td>
</tr>
<tr>
<td>Anastasiades C 1980&lt;sup&gt;22&lt;/sup&gt;</td>
<td>72</td>
<td>M</td>
<td>Nifedipine 400 Alprenolol 30</td>
<td>Dyspnoea, pulmonary edema</td>
<td></td>
<td>Cessation of nifedipine</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>M</td>
<td>Nifedipine 30 Propranolol 120</td>
<td>Dyspnoea, edema of the legs, congestive heart failure</td>
<td></td>
<td>Cessation of treatment</td>
</tr>
</tbody>
</table>
insufficiency, which points in the direction of an interaction between metoprolol and verapamil.

The efficacy and safety data supporting the use of CCBs and BBs primarily comes from monotherapy, and clinical studies on the combined use mainly concern the treatment of angina pectoris in patients with chronic coronary heart disease.7–9 Worsening of myocardial function, such as hypotension, bradycardia, and AV block, might be expected to occur more often with combination therapy rather than therapy with either drug alone.7,10 Some authors found that cardiac risk increases by left ventricular dysfunction, aortic stenosis, low-pulse rate, or large doses of either drug10–14; however, other authors describe cases in which the ventricular function was normal or near normal and incidents have often occurred at normal doses of both drugs (Table 4).15

That the combined use of CCBs and BBs may cause adverse cardiovascular effects was seen in the clinical trials investigating combined use, and it has been clinically documented (Table 4).7,12,15-24 The precise nature of the mechanism is uncertain, and it may be due to the combination of a number of actions, both pharmacokinetic and pharmacodynamic.

An existing interaction between metoprolol and verapamil is well documented. Verapamil has been shown to affect the clearance of the lipophilic BBs, propranolol, and metoprolol (both metabolized in the liver), but to have no effect on the pharmacokinetics of atenolol, a hydrophilic compound excreted unchanged in the urine.11,25–27 McCourty et al investigated the effect of verapamil on the pharmacokinetics and pharmacodynamics of propranolol in six patients and found an increase in the area under the curve (AUC) of propranolol, that however, did not reach statistical significance.11 The six patients received the same doses, but AUC of propranolol differed statistically significantly between the subjects. One patient was withdrawn from the study as his ECG showed atioventricular dissociation with a ventricular rate of 37 bpm. His AUC is not presented in the paper. Concomitant administration of metoprolol with verapamil produced a significant increase in peak plasma concentration and in the AUC of propranolol by 85%, respectively 35%.25,26 Keech et al investigated the pharmacokinetic interaction between metoprolol and verapamil. This interaction might have caused an increase in concentrations, the patient died from a serious cardiac insufficiency, which points in the direction of an interaction between metoprolol and verapamil. This interaction might have been due to CYP2D6 PM genotype with high metoprolol concentrations and also have a slow elimination of metoprolol.

In the above case, a junior MD ordered one single tablet of metoprolol 50 mg, and for some reason, the blood concentration of metoprolol was much higher than expected almost 24 hours later. Even though postmortem redistribution might have caused an increase in concentrations, the patient died from a serious cardiac insufficiency, which points in the direction of an interaction between metoprolol and verapamil. This interaction might have been strong due to CYP2D6 PM status which could be a special vulnerability factor for the combination of verapamil and metoprolol.

The inhibitory effects of six CCBs, including verapamil and diltiazem, on three major CYP isoenzymes, CYP2C9, CYP2D6, and CYP3A4, were examined in liver microsomes.27 All six compounds reversibly inhibited CYP2D6, CYP2C9, and with increasing potency, CYP3A4.

Four metabolizer phenotypes characterize drug metabolism via CYP2D6 in vivo: ultrarapid metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM).28 Based on the genotype involved, the plasma concentration of metoprolol may range from subtherapeutic levels in the UM group to supratherapeutic and potentially toxic concentrations in the PM group, increasing the probability of adverse effects such as hypotension and bradycardia.29 A systematic review from 2013 found differences in peak plasma metoprolol concentration, AUC, elimination half-life, and apparent oral clearance that were 2.3-, 4.9-, 2.3-, and 5.9-fold between EM and PM, respectively and 5.3-, 13-, 2.6-, and 15-fold between UM and PM (all \(P < .001\)), respectively.30

The ratio between tramadol (TRA) and the metabolite O-desmethyltramadol (ODT) can for living individuals be used to estimate an individual's CYP2D6 phenotype.31 In a postmortem setting, the ratio has been used to estimate an individual's CYP2D6 genotype.32,33 A TRA/ODT ratio above 15–30 indicates CYP2D6 PM genotype. In this case, the TRA/ODT ratio was 15 indicating CYP2D6 PM genotype. The ratio TRA/ODT is not that specific in predicting CYP2D6 PM phenotype, but Fonseca et al found that a ratio between N-desmethyltramadol (NDT) and ODT above seven was a more predictive ratio for CYP2D6 PM genotype.33 In this case, NDT/ODT = 56 gives a strong indication of our patient being CYP2D6 PM genotype.

Another possible interaction caused by verapamil could occur via inhibition of organic cation transporter OCT1 which would cause a reduced uptake of metoprolol into the hepatocytes, and thus, a decrease in metabolism.34 This means that individuals with CYP2D6 PM status who receive a combination of verapamil and metoprolol would be especially in risk of attaining high metoprolol concentrations and also have a slow elimination of metoprolol.

In the above case, a junior MD ordered one single tablet of metoprolol 50 mg, and for some reason, the blood concentration of metoprolol was much higher than expected almost 24 hours later. Even though postmortem redistribution might have caused an increase in concentrations, the patient died from a serious cardiac insufficiency, which points in the direction of an interaction between metoprolol and verapamil. This interaction might have been strong due to CYP2D6 PM status which could be a special vulnerability factor for the combination of verapamil and metoprolol.

CONFLICT OF INTEREST
None declared.

AUTHORS CONTRIBUTIONS
Eva A. Sædder: was responsible for writing the manuscript and for medical interpretation of blood samples and toxicology (first author). Asser Hedegård Thomsen: was the responsible forensic pathologist and performed the autopsy. Jørgen
Bo Hasselstrøm: was responsible for the laboratory tests performed. Jakob Ross Jornil: was the responsible analytical chemist in the case. All authors: read, contributed to, and approved the final manuscript.

ORCID

Eva A. Saedder https://orcid.org/0000-0003-4905-1004

REFERENCES


How to cite this article: Saedder EA, Thomsen AH, Hasselstrøm JB, Jornil JR. Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review. "Clin Case Rep". 2019;00:1–7. https://doi.org/10.1002/ccr3.2393